Wheeler DC, Toto RD, Stefansson BV, et al. - Given that a reduction in renal failure risk as well as prolonged survival was conferred by dapagliflozin in patients with chronic kidney disease with and without type 2 diabetes, including those with immunoglobulin A (IgA) nephropathy, in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial, so, researchers herein included participants exhibiting estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m ² and urinary albumin-to-creatinine ratio 200-5000 mg/g (22.6-565 mg/mol). These were randomly assigned to dapagliflozin 10mg or placebo, as adjunct to standard care. A sustained reduction in eGFR of 50% or more, end-stage kidney disease, or death from a kidney disease-associated or cardiovascular reason, was the primary composite endpoint. Occurrence of primary outcome was seen in six (4%) participants receiving dapagliflozin and 20 (15%) receiving placebo. With dapagliflozin and placebo, estimated mean rates of eGFR reduction were −3.5 and −4.7 mL/min/1.73m ² /year, respectively. Overall, dapagliflozin displayed a favorable safety profile and conferred a reduction in the risk of chronic kidney disease progression in participants suffering from IgA nephropathy.